SODIUM NITROPRUSSIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sodium Nitroprusside, and when can generic versions of Sodium Nitroprusside launch?
Sodium Nitroprusside is a drug marketed by Abraxis Pharm, Amneal, Amphastar Pharms Inc, Avet Lifesciences, Baxter Hlthcare, Be Pharms, Caplin, Chartwell Rx, Cipla, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Micro Labs, Mylan Labs Ltd, Nexus, Norvium Bioscience, Sagent Pharms Inc, Slate Run Pharma, Somerset Theraps Llc, Sun Pharm, Teva Parenteral, and Xiromed. and is included in twenty-three NDAs.
The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sodium Nitroprusside
A generic version of SODIUM NITROPRUSSIDE was approved as sodium nitroprusside by SAGENT PHARMS INC on December 8th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SODIUM NITROPRUSSIDE?
- What are the global sales for SODIUM NITROPRUSSIDE?
- What is Average Wholesale Price for SODIUM NITROPRUSSIDE?
Summary for SODIUM NITROPRUSSIDE
| US Patents: | 0 |
| Applicants: | 22 |
| NDAs: | 23 |
| Finished Product Suppliers / Packagers: | 15 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Clinical Trials: | 76 |
| Patent Applications: | 38 |
| Drug Prices: | Drug price information for SODIUM NITROPRUSSIDE |
| DailyMed Link: | SODIUM NITROPRUSSIDE at DailyMed |
Recent Clinical Trials for SODIUM NITROPRUSSIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Egymedicalpedia | Early Phase 1 |
| Tanta University | N/A |
| Kafrelsheikh University | N/A |
Pharmacology for SODIUM NITROPRUSSIDE
| Drug Class | Vasodilator |
| Physiological Effect | Vasodilation |
Anatomical Therapeutic Chemical (ATC) Classes for SODIUM NITROPRUSSIDE
US Patents and Regulatory Information for SODIUM NITROPRUSSIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Pharm | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 070031-001 | Jan 17, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Slate Run Pharma | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 214199-001 | Aug 25, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Slate Run Pharma | SODIUM NITROPRUSSIDE | sodium nitroprusside | SOLUTION;INTRAVENOUS | 215846-002 | Aug 26, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Caplin | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 211016-001 | Nov 29, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
